PTG-300 in Subjects With Hereditary Hemochromatosis

NCT04202965 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Hemochromatosis

Interventions

DRUG: PTG-300

Sponsor

Protagonist Therapeutics, Inc.